Because expression of the glucagon receptor in the liver alone is sufficient to produce severe diabetes in glucagon receptor-null mice lacking functional β-cells [51], suppression of glucagon-induced hepatic glucose output would appear to be a good target for T2D therapy. This evidence concerns the gene GCGR and type 2 diabetes mellitus.